← Leaderboards
Adam J Atherly
University Of Colorado Denver
$2,282,503
Attributed
$2,282,503
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $578.9K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,821,927 · 4
AHRQ$460,576 · 1
By mechanism
R61$626,943 · 1
R33$578,913 · 1
R01$460,576 · 1
R21$424,071 · 1
R03$192,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Paul Werner Buehler$4,588,385
- David Charles Irwin$10,493,842
- Andre Francis Palmer$9,637,181
- Douglas K Novins$3,835,300
- Walter Perry Dickinson$20,394,243
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCostStructureCaringMedicareTrendPoliciesPharmaceutical PreparationsElementsLogit ModelsUnited States Centers For Medicare And Medicaid ServicesBeneficiarySurveysProgramsPaymentProviderFundingFeesIncentivesDesignServicesBlack PopulationsBlack AmericanAge Of Onset
Grant awards (10)
Measuring the Impact of the Value Flower and Unobserved Heterogeneity on the Cost Effectiveness and Use of Novel Treatments for Alzheimer's Disease and Related Dementias$578,913
R33 · FY2025 · AG · contact PI
Measuring the Impact of the Value Flower and Unobserved Heterogeneity on the Cost Effectiveness and Use of Novel Treatments for Alzheimer's Disease and Related Dementias$305,718
R61 · FY2024 · AG · contact PI
Measuring the Impact of the Value Flower and Unobserved Heterogeneity on the Cost Effectiveness and Use of Novel Treatments for Alzheimer's Disease and Related Dementias$321,225
R61 · FY2023 · AG · contact PI
The effects of medicare advantage payment reductions on low income elderly medicare beneficiaries$151,003
R01 · FY2016 · HS · contact PI
The effects of medicare advantage payment reductions on low income elderly medicare beneficiaries$76,460
R01 · FY2016 · HS · contact PI
The effects of medicare advantage payment reductions on low income elderly medicare beneficiaries$233,113
R01 · FY2015 · HS · contact PI
Implications of Switching Costs for Medicare Premium Support$76,000
R03 · FY2014 · AG · contact PI
Implications of Switching Costs for Medicare Premium Support$116,000
R03 · FY2013 · AG · contact PI
Effects of changes in Medicaid physician fees on use of preventive care$224,415
R21 · FY2012 · HD · contact PI
Effects of changes in Medicaid physician fees on use of preventive care$199,656
R21 · FY2011 · HD · contact PI